Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics presented three poster abstracts at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The data highlights cognitive and functional outcomes from the Phase 3 ENCORE trial of AXS-12 in narcolepsy with cataplexy, as well as post-hoc analyses of solriamfetol in narcolepsy and OSA. A third poster examined symptom burden and quality of life in patients with residual cataplexy based on the CRESCENDO survey.
Key figures
- Drug Name
- AXS-12, solriamfetol
- Phase Of Trial
- Phase 3
- Conference
- SLEEP 2026
- Poster count
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.